Research programme: anti-MICA monoclonal antibody - Innate Pharma

Drug Profile

Research programme: anti-MICA monoclonal antibody - Innate Pharma

Alternative Names: IPH-43; IPH-4301

Latest Information Update: 08 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innate Pharma
  • Class Monoclonal antibodies
  • Mechanism of Action Natural killer cell receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Mar 2017 Preclinical development is ongoing in France
  • 18 Apr 2016 Preclinical data presented at the American Association for Cancer Research (AACR-2016)
  • 18 Apr 2016 Innate Pharma plans a phase I trial for Cancer in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top